<DOC>
	<DOC>NCT00880490</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of inhaled PT005 compared to placebo and Formoterol Fumarate (Foradil Aerolizer) in patients with moderate to severe chronic obstructive pulmonary disease (COPD).</brief_summary>
	<brief_title>Study to Evaluate the Safety and Efficacy of Inhaled PT005 in Patients With Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<criteria>Signed written informed consent 40 80 years of age Fluency in written and spoken English Females of nonchild bearing potential or females of child bearing potential with negative pregnancy test; and acceptable contraceptive methods Current/former smokers with at least a 10 packyear history of cigarette smoking A measured postsalbutamol FEV1/FVC ratio of &lt; or = 0.70 A measured postsalbutamol FEV1 &gt; or = 40 and &lt; or = 80% of predicted normal values Demonstrated reversibility to a short acting beta agonist by either &gt;12% and &gt;150 ml improvement in baseline FEV1, 30 minutes following administration of 4 puffs of salbutamol MDI or an absolute improvement of &gt;200 ml in baseline FEV1, 30 minutes following administration of 4 puffs of salbutamol MDI. Competent at using the inhalation device Women who are pregnant or lactating Primary diagnosis of asthma Alpha1 antitrypsin deficiency as the cause of COPD Active pulmonary diseases Prior lung volume reduction surgery Abnormal chest Xray (or CT scan) not due to the presence of COPD Hospitalized due to poorly controlled COPD within 24 weeks of Screening Poorly controlled COPD in prior 6weeks, defined as the occurrence of acute worsening of COPD requiring corticosteroids or antibiotics or acute worsening of COPD requiring treatment prescribed by a physician Clinically significant medical conditions Lower respiratory tract infection requiring antibiotics in past 6 weeks Clinically significant abnormal ECG Clinically significant uncontrolled hypertension Positive Hepatitis B surface antigen or Hepatitis C antibody Cancer that has not been in complete remission for at least 5 years History of hypersensitivity to any beta2agonists or any study drug component History of severe milk protein allergy Known or suspected history of alcohol or drug abuse Medically unable to withhold short acting bronchodilators for 8hours Use of the medications below in specified time interval prior to Screening: 12weeks: depot corticosteroids, intraarticular corticosteroids; 4 weeks: ICS &gt;1000 Î¼g/day of fluticasone propionate or equivalent, nonpotassium sparing diuretics, Pglycoprotein inhibitors, CYP3A4 inhibitors; 1 week: tiotropium; 48 hours: oral beta agonists, long acting beta agonists, theophylline, zariflukast, montelukast, zileuton; 8 hours: ipratropium or ipratropium/salbutamol combination product, inhaled short acting beta agonists, xanthine containing foods Use of the following medications is prohibited: tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, betaadrenergic antagonists, anticonvulsants (barbiturates,hydantoins, and carbamazepine and phenothiazines Receiving longtermoxygen or nocturnal oxygen therapy for &gt;12 hours a day Diagnosis of sleep apnea that is uncontrolled Participation in acute phase of pulmonary rehabilitation in prior 4 weeks or will enter acute phase of pulmonary rehabilitation program during study Unable to comply with study procedures Affiliated with Investigator site Questionable validity of consent A positive drug of abuse test at Screening lives prior to Screening, whichever is longer</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>COPD</keyword>
</DOC>